Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Lab-on-a-Chip, Microfluidics & Microarrays World Congress 2016

Bernhard Weigl's Biography



Bernhard Weigl, Principal Investigator, Flow Based Diagnostics, Intellectual Ventures/Global Good, University of Washington

Dr. Bernhard H Weigl is Principal Investigator at Intellectual Ventures/Global Good which is funded and led by Bill Gates, Microsoft Co-Founder.

Dr. Weigl is also Affiliate Professor at the University of Washington, Department of Bioengineering. Until recently he was a Senior Technology Officer at PATH, Portfolio Leader for Non-communicable Disease Diagnostics and the former Director of the National Institutes of Health-funded Center for Point-of-Care Diagnostics for Global Health. Dr. Weigl led the PATH Diagnostics Group where he oversaw global health diagnostics programs funded by a variety of sources such as NIAID and NIBIB, the Grand Challenges program of the Bill and Melinda Gates Foundation, USAID, and the PATH Health Innovation Portfolio. His work focuses on diagnostic technology R&D including strip-based immunoassays, instrument-free molecular assays, and a variety of isothermal amplification assays for low resource settings. Before joining PATH, both at the University of Washington and at Micronics, Inc. (Redmond, Washington, where he was a scientific cofounder; Micronics is now a wholly owned subsidiary of Sony Corporation of America), Dr. Weigl led teams that developed both instrument-based and stand-alone microfluidic medical diagnostic disposables. His scientific interests include traditional and paper-based microfluidics as well as any diagnostic platform that allow simplification and integration of previously complex assays. As chronic diseases, and especially diabetes, are emerging as a major health threat in developing countries he is now also focusing on their diagnosis, screening, and treatment. Other areas of interest include diagnostics-related health systems topics such as more rational diagnostic algorithms, and evaluation and selection of the most appropriate diagnostic tool for a particular application using metrics beyond sensitivity and specificity. He has led projects across the diagnostics value chain, from invention and proof of principle though product introduction and support. He received his M.Sc (Mag. rer. nat.) and Ph.D. (Dr. rer. nat.) from Karl-Franzens-University Graz and has completed post-doctoral studies at the University of Southampton and the University of Washington. He has authored more than 100 scientific papers and is an inventor on over 80 US patents and patent applications.

Bernhard Weigl Image

High-Performance Rapid Diagnostic Tests

Monday, 26 September 2016 at 17:00

Add to Calendar ▼2016-09-26 17:30:002016-09-26 18:30:00Europe/LondonHigh-Performance Rapid Diagnostic TestsLab-on-a-Chip, Microfluidics and Microarrays World Congress 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com

Lateral flow and similar rapid diagnostic assays (LFAs) are easy to use and manufacture, low cost, rapid, require little or no equipment to operate, and do not need to be refrigerated. However, they are generally not considered to be very sensitive or able to provide a quantitative result. Our group believes that this lack of sensitivity is not a fundamental property of LFAs but rather a consequence of the way they are developed, manufactured, and marketed. Historically, most lateral flow tests were developed and optimized by relatively small manufacturers with limited R&D capabilities and budgets, and were generally used only for analytical targets prevalent at high concentration in patient’s samples that were relatively easy to measure. In contrast, our group’s mission is to develop LFA-based assays for use in global health applications that are as sensitive as the best conventional diagnostic assays (in some cases even better) while retaining all their cost, simplicity, and usability advantages.

High-Performance Rapid Diagnostic Tests

Monday, 26 September 2016 at 17:00

Add to Calendar ▼2016-09-26 17:30:002016-09-26 18:30:00Europe/LondonHigh-Performance Rapid Diagnostic TestsLab-on-a-Chip, Microfluidics and Microarrays World Congress 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com

Lateral flow and similar rapid diagnostic assays (LFAs) are easy to use and manufacture, low cost, rapid, require little or no equipment to operate, and do not need to be refrigerated. However, they are generally not considered to be very sensitive or able to provide a quantitative result. Our group believes that this lack of sensitivity is not a fundamental property of LFAs but rather a consequence of the way they are developed, manufactured, and marketed. Historically, most lateral flow tests were developed and optimized by relatively small manufacturers with limited R&D capabilities and budgets, and were generally used only for analytical targets prevalent at high concentration in patient’s samples that were relatively easy to measure. In contrast, our group’s mission is to develop LFA-based assays for use in global health applications that are as sensitive as the best conventional diagnostic assays (in some cases even better) while retaining all their cost, simplicity, and usability advantages.


Add to Calendar ▼2016-09-26 00:00:002016-09-28 00:00:00Europe/LondonLab-on-a-Chip, Microfluidics and Microarrays World Congress 2016Lab-on-a-Chip, Microfluidics and Microarrays World Congress 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com